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PRELIMINARY AND SHORT REPORT
FAILURE OF STILBAMIDINE TO ARREST EXPERIMENTAL
BLASTOMYCOSIS IN MICE*
JAN SCHWARZ, M.D. AND SALVADOR ADRIANO, M.D.
Attempts at treatment of North American blastomycosis have beea rather unsatis-
factory in the past and the introduction of such potent drugs as propamidine and stilbami-
dine offered promise. In this connection, we have encountered no experimental work except
Heilman's paper (3) on the effects of stilbamidine in hiastomycosis in mice. Our own work
was concluded prior to the publication of this paper.
MATERIAL AND METHODS
White mice of the same breed and of an average weight of 20 grams were inoculated
intravenously with ground mycelial phase of Blastomyces dermatitidis. Care was taken to
shake the inoculum suspended in saline frequently in order to prevent sediment formation.
Twenty-one mice were injected and subsequently separated into 2 groups. With 10 animals
serving as controls, eleven mice were given stilbamidine (2 milligrams per kilogram body
weight) S days after inoculation. The drug was administered each day in a single subcu-
taneous injection. The dosage was selected as proportionate to that recommended for
man. All animals died spontaneously except the last control mouse which was killed after
61 days. Stilbamidine was used immediately after mixing and the solution was kept from
any undue exposure to light.
RESULTS
Gross inspection and histologic examination of the lungs revealed blastomycotic foci in
all instances. The lesions were classified as "spot-like", "moderate" and "massive" in-
volvement and the results are represented in Table 1. The disease was not arrested in any
instance up to a maximum of 17 days of treatment and the extent of the lung lesion was
obviously related to time between inoculation and death, rather than length of treatment.
DIscUSSION
The treatment of chronic infectious diseases can be evaluated clinically only by a large
series of observations. Since blastomycosis is a rather uncommon disease, it seems obvious
that the evaluation of controlled experimental treatment in animals will be more conclusive
in determining the efficacy of one or another agent. From our experience, we have concluded
that no beneficial effect may be anticipated using a single daily dose of 2 milligrams per
kilogram body weight of stilbamidine in mice. The very much larger dose Heilman (2) used
seems to benefit the animals, but the objection to such dosage is apparent. In the animals
which showed improvement, 2.5 to 12.5 times the level considered safe in human beings was
used. Potential toxicity of the drug cannot be lightly considered since Cohen (1) has ob-
served 2 cases of hepatic necrosis after stilbamidine therapy in men. We have experienced
an identical case and know from Dr. M. L. Fureolow about at least one more such lethal
accident.
Snapper (6) has stated that stilbamidine is too toxic to be used in man and places his
faith in 2-hydroxy-stilbamidine. It seems advisable to warn the profession to use stilbami-
dine with the greatest caution. Trigeminal lesions seem to occur with great frequency and
at least 4 cases of lethal necrosis of the liver can be attributed to the drug.
* From the Clinical Laboratories, Jewish Hospital, Cincinnati Ohio and the Laboratory
of Mycology (Departments of Dermatology and Pathology) Cincinnati General Hospital.
Received for publication December 29, 1952.
329
330 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
The temporary clearing of skin lesions in blastomycosis as reported by Schoenbach (4, 5)
has been observed with many therapeutic regimens and indeed may even occur spontane-
ously. A follow up study of years will be necessary before the benefits of stilbamidine treat-
ment can be proven.
TABLE 1
Results of treatment of mice inoculated with mycelial phase of blastomyces dermatitidis
ANIMALS DEAD ACcORDING TO DAY
DAYS AFTER Treated animals Controls
INOCULATION
________________________
—
Number TIwt
—
Chararter ot iesiou Number Chararter ot lesion
12 1 4 Not examinedt
13 3 5 Spot-like
14 1 Not examinedt
15 2 7 Spot-like
16 1 Moderately severe
18 1 Not examinedt
1 Moderately severe
20 1 Extensive
22 3 Extensive
23 1 Extensive
26 1 17 Extensive
28 1 17 Extensive
30 1 17 Moderately severe
32 1 17 Extensive
36 1 17 Extensive
61 1 Moderately severe
* Eaten by mice in same cage.
5UMMARY
Two milligrams per kilogram body weight of stilbamidine given in a single daily subcu-
taneous injections to mice did not inhibit the development of severe lethal pulmonary
blastomycosis in mice.
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